Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.
A 36-year-old started using finasteride (0.3-0.5mg daily), 5% minoxidil foam, and weekly dermarolling/dermapen treatments to address hair loss. They also began taking supplements for low ferritin and vitamin D, hoping to improve hair thickness and cover a bald spot.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
User follows a hair loss protocol with topical finasteride, minoxidil, RU58841, stemoxydine, and microneedling. They plan to get a hair transplant at month 9 and ask for opinions on their progress.
A user shared a six-month update on hair improvement using Pyrilutamide and Minoxidil, noting significant hair regrowth and strength. Some participants questioned the legitimacy of the results and the source of Pyrilutamide.
The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.
A 46-year-old male shared his 3-week progress using HIMS serum with Finasteride 0.3% and Minoxidil 6%, showing improvement without noticeable shedding. His routine includes vitamins, a healthy diet, and specific hair care practices like microneedling and using caffeine solution.
A user shared their experience with scalp micropigmentation (SMP) after one year. They discussed using Minoxidil, finasteride, and RU58841 as treatments for hair loss.
A user experienced significant hair regrowth using finasteride and minoxidil over four years, despite side effects like seborrheic dermatitis, urinary changes, and water retention. They were satisfied with the results and maintained a strong physique.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
A user shared their 4-month hair regrowth progress using 0.5mg dutasteride and 2.5mg minoxidil, reporting no side effects and significant improvement. The conversation includes discussions on treatment choices, dosages, and personal experiences with hair loss treatments.
Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.
A user shared their 5-month progress in treating hair loss using HIMs topical finasteride and minoxidil, micro-needling with a 1.5mm needle, and RU-58841. The post includes progress pictures showing improvement from a NW7 hair loss stage.
A user shared their 4-month progress using oral minoxidil, finasteride, and derma rolling for hair loss. They reported positive results and expressed gratitude for the treatment.
A 26-year-old male shared progress photos showing hair improvement after nearly 5 months on oral Minoxidil (4mg), Dutasteride (0.5mg), and biotin (4mg). The photos show noticeable hair growth over time.
The user is using a regimen of topical Minoxidil and Finasteride, oral Minoxidil, and a thickening shampoo and conditioner. They report no side effects except increased body hair, which they don't mind.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
The user shared progress pictures showing hair improvement over four months using 1 mg finasteride and 5 mg minoxidil daily. They reported no significant side effects and plan to reduce the minoxidil dose once satisfied with the results.
A user shared their 4-month progress pictures after using Minoxidil, finasteride, micro-needling, Nizoral, and scalp massage for hair loss. They're now switching from topical to oral finasteride to maintain the results.
The user, Virtual_Force3845, shared their progress pictures after using Hims Fin/Min Spray consistently for 3-4 months. They are excited about the progress and have not experienced any side effects. Other users in the conversation shared their own experiences and asked questions about the treatment.
The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.